Skip to content
ASTRAL

Compound research

What literature relates to the CJC-1295 / Ipamorelin blend?

The blend combines two distinct research compounds. References are separated by constituent because studies of either constituent are not evidence for the combined commercial preparation.

View CJC-1295 / IpamorelinCheck batch records
Research compoundCJC-1295 / Ipamorelin
CAS number863288-34-0 / 170851-70-4
Molecular formulaBlend
Molecular weight3367.97 + 711.85 g/mol

Source trail

Selected references

  1. Human pharmacology study

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

    Teichman SL, Neale A, Lawrence B, et al. Journal of Clinical Endocrinology & Metabolism (2006).

    Characterizes CJC-1295 as a GHRH analog; it does not evaluate Astral's blend.

    PMID 16352683 · DOI 10.1210/jc.2005-1536

  2. Preclinical pharmacology study

    Ipamorelin, the first selective growth hormone secretagogue.

    Raun K, Hansen BS, Johansen NL, et al. European Journal of Endocrinology (1998).

    Characterizes ipamorelin receptor activity and selectivity; it does not evaluate the blend.

    PMID 9849822 · DOI 10.1530/eje.0.1390552

How to interpret this page

These sources establish research context only. They do not verify an Astral lot, support dosing or human use, or prove safety or efficacy. Use the lot-specific COA for analytical evidence.

Editorially curated and source-verified; not independently peer-reviewed by Astral. Last source check: 2026-07-21. Read the editorial policy.